Entolimod may be a promising treatment option for many solid tumors

Posted on by admin

The first clinical study of the anticancer effects of the novel agent entolimod are now available. Findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
SOURCE: Latest Science News — ScienceDaily – Read entire story here.

Related posts:

  1. Microscopic sonic screwdriver invented Engineers have created tiny acoustic vortices and used them to grip and spin microscopic particles suspended in water. ...
  2. Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial. ...
  3. Rewriting the book on chemo-resistant cancers with a DNA library Researcher are finding out why ovarian cancer is resistant to certain types of chemo and hope to eventually identify a different drug target. ...
  4. Altered pain processing in patients with cognitive impairment People with dementia and other forms of cognitive impairment (CI) have altered responses to pain, with many conditions associated with increased pain sensitivity, concludes a new research review. ...
  5. Many children with asthma have reaction to peanuts, but do not know it In recent years and months, peanut allergies in children have been in the news frequently, as scientists reveal new insights into why more and more children are developing them and what can be done to avoid them. However, until now, few have studied the connection between peanut allergy and childhood asthma. ...

Related Posts